跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
clostridium butyricum + bifidobacterium
首页
药物
clostridium butyricum + bifidobacterium
clostridium butyricum + bifidobacterium
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
ADJUNCTIVE AGENT FOR LAVAGING THE ALIMENTARY CANAL COMPRISING BUTYRIC ACID BACTERIUM AND/OR LACTIC ACID BACTERIUM
US 2009257992 A1
申请人: MIYARISAN PHARMA
优先权: 2006
US
3 件公开
METHODS OF REDUCING FOOD CRAVINGS AND RELATED COMPOSITIONS
EP 4791416 A1
申请人: PENDULUM THERAPEUTICS INC
优先权: 2023
EP
WO
2 件公开
Microbial preparation for curing intestinal diseases
CN 1391905 A
申请人: DONGFANG BAIXIN BIOLOG TECHNOL
优先权: 2001
CN
Application of clostridium butyricum, bacillus coagulans and bifidobacterium in preparation of medicament for treating cold cool purging and drinking purging
CN 102008511 A
申请人: QINGDAO EASTSEA PHARMACEUTICAL CO LTD
优先权: 2006
CN
Application of composition of clostridium butyricum and bifidobacterium dual live bacteria preparation and anticancer medicament in preparation of medicament for treating intestinal cancer
CN 103202861 A
申请人: SHANDONG KEXING BIOPRODUCTS CO LTD
优先权: 2013
CN
Vaginal probiotic suppository
CN 104622914 A
申请人: ZHAN MEIHUA
优先权: 2015
CN
Method for researching preventive effect of combined clostridium butyricum and bifidobacterium powder on NEC (neonatal necrotizing enterocolitis)
CN 104857026 A
申请人: UNIV XINXIANG MEDICAL
优先权: 2015
CN
Preparation method of composite probiotic agent for preventing and treating diabetes and controlling body weight
CN 106138114 A
申请人: FOSHAN YANHUI BIOLOGICAL TECH CO LTD
优先权: 2016
CN
Composite probiotic liquid for preventing diabetes and controlling body weight and preparation method thereof
CN 106176833 A
申请人: FOSHAN YANHUI BIOTECHNOLOGY CO LTD
优先权: 2016
CN
Lactobacillus composition for treating constipation and preparation method of lactobacillus composition
CN 107050062 A
申请人: JIANGXI GOOD ALLY TECH CO LTD
优先权: 2016
CN
第 1 / 5 页
上一页
下一页
药物
反馈